GMAB – Genmab A/S

Float Short %

1.83

Margin Of Safety %

Put/Call OI Ratio

0.03

EPS Next Q Diff

EPS Last/This Y

0.18

EPS This/Next Y

-0.62

Price

31.74

Target Price

33.97

Analyst Recom

1.85

Performance Q

15.25

Relative Volume

0.37

Beta

0.9

Ticker: GMAB

18 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2025-11-10	GMAB	29.07	0.17	0.03	3220
2025-11-11	GMAB	30.32	0.17	0.01	3232
2025-11-12	GMAB	30.48	0.17	0.09	3328
2025-11-13	GMAB	30.23	0.17	0.02	3356
2025-11-14	GMAB	30.26	0.17	0.02	3362
2025-11-17	GMAB	30.42	0.17	0.00	3411
2025-11-18	GMAB	30.32	0.15	0.17	3819
2025-11-19	GMAB	30.56	0.15	0.16	3826
2025-11-20	GMAB	30.03	0.15	0.35	3817
2025-11-21	GMAB	30.44	0.15	0.08	3843
2025-11-24	GMAB	30.8	0.05	0.00	2354
2025-11-25	GMAB	31.4	0.05	0.06	2381
2025-11-26	GMAB	31.92	0.05	0.13	2406
2025-12-01	GMAB	31.41	0.03	0.01	4572
2025-12-02	GMAB	31.7	0.04	0.00	4111
2025-12-03	GMAB	31.67	0.04	0.01	4170
2025-12-04	GMAB	32.02	0.03	0.02	4250
2025-12-05	GMAB	31.75	0.03	0.11	4275
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

18 items 1 of 1

18 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-11-10	GMAB	29.06	-48.0	-31.2	1.71
2025-11-11	GMAB	30.31	-48.0	31.6	1.88
2025-11-12	GMAB	30.48	-48.0	150.7	1.88
2025-11-13	GMAB	30.24	-48.0	81.8	1.88
2025-11-14	GMAB	30.26	-48.0	89.8	1.88
2025-11-17	GMAB	30.42	-48.0	112.1	1.88
2025-11-18	GMAB	30.32	-48.0	82.1	1.88
2025-11-19	GMAB	30.57	-48.0	106.3	1.88
2025-11-20	GMAB	30.05	-48.0	-88.0	1.88
2025-11-21	GMAB	30.46	-48.0	54.3	1.88
2025-11-24	GMAB	30.81	-48.0	141.1	1.88
2025-11-25	GMAB	31.40	-48.0	124.4	1.88
2025-11-26	GMAB	31.93	-48.0	221.1	1.88
2025-12-01	GMAB	31.40	-48.0	126.4	1.88
2025-12-02	GMAB	31.71	-48.0	143.9	1.88
2025-12-03	GMAB	31.68	-48.0	120.2	1.88
2025-12-04	GMAB	32.02	-48.0	184.8	1.88
2025-12-05	GMAB	31.74	-48.0	163.6	1.88
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

18 items 1 of 1

18 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-11-10	GMAB	0	0.32	0
2025-11-11	GMAB	0	0.32	1.08
2025-11-12	GMAB	0	0.32	1.71
2025-11-13	GMAB	0	0.32	1.71
2025-11-14	GMAB	0	0.32	1.71
2025-11-17	GMAB	0	0.36	1.71
2025-11-18	GMAB	0	0.36	1.71
2025-11-19	GMAB	0	0.36	1.71
2025-11-20	GMAB	0	0.36	1.71
2025-11-21	GMAB	0	0.36	1.71
2025-11-24	GMAB	0	0.39	0
2025-11-25	GMAB	0	0.39	1.71
2025-11-26	GMAB	0	0.39	1.83
2025-12-01	GMAB	0	0.47	1.83
2025-12-02	GMAB	0	0.47	1.83
2025-12-03	GMAB	0	0.47	1.83
2025-12-04	GMAB	0	0.47	1.83
2025-12-05	GMAB	0	0.47	1.83
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

18 items 1 of 1

Last Quarter Act. EPS

0.65

Avg. EPS Est. Current Quarter

0.43

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

0.47

Beta

0.9

Average Sales Estimate Current Quarter

6584

Average Sales Estimate Next Quarter

5976

Fair Value

38.56

Quality Score

100

Growth Score

Sentiment Score

Actual DrawDown %

35.3

Max Drawdown 5-Year %

-63.1

Target Price

33.97

P/E

13.48

Forward P/E

19.61

PEG

1.78

P/S

5.44

P/B

3.4

P/Free Cash Flow

15.65

EPS

2.35

Average EPS Est. Cur. Y

1.88

EPS Next Y. (Est.)

1.26

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

41.34

Relative Volume

0.37

Return on Equity vs Sector %

-1.8

Return on Equity vs Industry %

13.1

EPS 1 7Days Diff

EPS 1 30Days Diff

0.17

EBIT Estimation

163.6

Genmab A/S

Sector: Healthcare

Industry: Biotechnology

Employees: 2681

Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large Bcell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy. It is also developing Epcoritamab for R/R DLBCL and FL, first line DLBCL and FL, B-cell non-Hodgkin lymphoma, R/R chronic lymphocytic leukemia and Richter's syndrome, and aggressive mature B-cell neoplasms in pediatric patients; tisotumab vedotin for solid tumors; Acasunlimab for solid tumors and non-small cell lung cancer (NSCLC); Rinatabart Sesutecan for platinum resistant ovarian cancer and solid tumors; GEN1042, GEN1059, GEN1055, and GEN1057 for solid tumors; GEN3014 for hematologic malignancies; GEN1160 for advanced solid and liquid tumors; and GEN1107 and GEN1286 for advanced solid tumors. In addition, the company offers DARZALEX/DARZALEX FASPRO for multiple myeloma (MM) and light-chain Amyloidosis; RYBREVANT for NSCLC; TECVAYLI and TALVEY for R/R MM; Kesimpta for Relapsing multiple sclerosis; and TEPEZZA for thyroid eye disease. Further, it is developing Amivantamab for recurrent/metastatic head and neck cancer, and advanced or metastatic colorectal cancer; Amlenetug for multiple system atrophy; Inclacumab for vaso-occulsive crises in sickle cell diseases; and Mim8 for hemophilia A. The company has a collaboration agreement with AbbVie Inc., Pfizer Inc., BioNTech SE, Johnson & Johnson, Novartis International AG, Medarex, Inc., ADC Therapeutics SA, Bristol Myers Squibb Corporation, Lundbeck A/S, Amgen Inc., Immatics, Novo Nordisk A/S, CureVac AG, and argenx. Genmab A/S was incorporated in 1998 and is headquartered in Copenhagen, Denmark.

stock quote shares GMAB – Genmab A/S Stock Price stock today

news today GMAB – Genmab A/S stock forecast ,stock prediction 2023 2024 2025

marketwatch GMAB – Genmab A/S yahoo finance google finance

stock history GMAB – Genmab A/S invest stock market

stock prices GMAB premarket after hours

ticker GMAB fair value insiders trading

NVO – Novo Nordisk A/S

Float Short %

0.82

Margin Of Safety %

Put/Call OI Ratio

0.71

EPS Next Q Diff

EPS Last/This Y

19.55

EPS This/Next Y

-1.14

Price

47.86

Target Price

61.19

Analyst Recom

2.25

Performance Q

-11.83

Relative Volume

0.91

Beta

0.67

Ticker: NVO

18 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2025-11-10	NVO	45.96	0.81	0.40	1579618
2025-11-11	NVO	49.17	0.80	0.29	1643519
2025-11-12	NVO	50.27	0.79	0.46	1685426
2025-11-13	NVO	49.21	0.77	0.27	1733361
2025-11-14	NVO	48.11	0.75	0.49	1787813
2025-11-17	NVO	48.49	0.77	0.47	1710834
2025-11-18	NVO	47.61	0.76	0.57	1768255
2025-11-19	NVO	49.02	0.75	0.52	1823587
2025-11-20	NVO	47.66	0.74	0.53	1870798
2025-11-21	NVO	47.65	0.74	0.70	1927598
2025-11-24	NVO	45.22	0.71	0.56	1684222
2025-11-25	NVO	47	0.71	0.51	1754353
2025-11-26	NVO	48.73	0.70	0.58	1774482
2025-12-01	NVO	48.44	0.72	0.46	1677518
2025-12-02	NVO	47.48	0.72	0.38	1698555
2025-12-03	NVO	47.63	0.71	0.35	1730780
2025-12-04	NVO	48	0.71	0.82	1747737
2025-12-05	NVO	47.93	0.71	0.57	1758528
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

18 items 1 of 1

18 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-11-10	NVO	45.94	-6.9	1049.4	23.48
2025-11-11	NVO	49.15	-6.9	1857.2	22.90
2025-11-12	NVO	50.27	-6.9	743.0	22.90
2025-11-13	NVO	49.15	-7.4	-1046.5	22.87
2025-11-14	NVO	48.25	-7.4	-1405.9	22.87
2025-11-17	NVO	48.48	-7.4	-695.3	22.87
2025-11-18	NVO	47.53	-7.4	-1187.0	23.10
2025-11-19	NVO	49.00	-7.4	-206.4	23.10
2025-11-20	NVO	47.59	-7.4	-663.3	23.10
2025-11-21	NVO	47.64	-7.4	-716.8	23.10
2025-11-24	NVO	44.99	-7.4	-1579.4	23.10
2025-11-25	NVO	47.06	-7.4	506.0	23.10
2025-11-26	NVO	48.69	-7.4	294.5	23.10
2025-12-01	NVO	48.43	-7.5	-1167.5	23.10
2025-12-02	NVO	47.43	-7.4	-1414.2	23.11
2025-12-03	NVO	47.57	-7.4	-952.4	23.11
2025-12-04	NVO	48.00	-7.5	-1359.5	23.11
2025-12-05	NVO	47.86	-7.5	-1416.3	23.08
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

18 items 1 of 1

18 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-11-10	NVO	0.00	-1.93	0.79
2025-11-11	NVO	0.00	-1.93	0.79
2025-11-12	NVO	0.00	-1.93	0.84
2025-11-13	NVO	0.00	-1.93	0.84
2025-11-14	NVO	0.00	-1.93	0.84
2025-11-17	NVO	0.00	-1.66	0.84
2025-11-18	NVO	0.00	-1.66	0.84
2025-11-19	NVO	0.00	-1.66	0.84
2025-11-20	NVO	0.00	-1.66	0.84
2025-11-21	NVO	0	-1.66	0.84
2025-11-24	NVO	0	-0.75	0.84
2025-11-25	NVO	0	-0.75	0.84
2025-11-26	NVO	0	-0.75	0.82
2025-12-01	NVO	0	-1.57	0.82
2025-12-02	NVO	0	-1.57	0.82
2025-12-03	NVO	0	-1.57	0.82
2025-12-04	NVO	0	-1.57	0.82
2025-12-05	NVO	0	-1.57	0.82
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

18 items 1 of 1

Last Quarter Act. EPS

1.02

Avg. EPS Est. Current Quarter

5.87

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

-1.57

Beta

0.67

Average Sales Estimate Current Quarter

78167

Average Sales Estimate Next Quarter

76155

Fair Value

54.34

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

67.7

Max Drawdown 5-Year %

-68.5

Target Price

61.19

P/E

13.94

Forward P/E

13.29

PEG

2.08

P/S

3.45

P/B

7.95

P/Free Cash Flow

16.12

EPS

3.43

Average EPS Est. Cur. Y

23.08

EPS Next Y. (Est.)

21.94

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

32.76

Relative Volume

0.91

Return on Equity vs Sector %

34.2

Return on Equity vs Industry %

24.7

EPS 1 7Days Diff

EPS 1 30Days Diff

-0.42

EBIT Estimation

-1416.3

Novo Nordisk A/S

Sector: Healthcare

Industry: Drug Manufacturers - General

Employees: 78554

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with UNICEF to tackle childhood obesity; and with Valo Health, Inc. to discover and develop novel drug programmes for cardiometabolic space. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

stock quote shares NVO – Novo Nordisk A/S Stock Price stock today

news today NVO – Novo Nordisk A/S stock forecast ,stock prediction 2023 2024 2025

marketwatch NVO – Novo Nordisk A/S yahoo finance google finance

stock history NVO – Novo Nordisk A/S invest stock market

stock prices NVO premarket after hours

ticker NVO fair value insiders trading

ASND – Ascendis Pharma A/S

Float Short %

4.94

Margin Of Safety %

Put/Call OI Ratio

0.46

EPS Next Q Diff

1.56

EPS Last/This Y

4.22

EPS This/Next Y

6.56

Price

205.44

Target Price

254.83

Analyst Recom

Performance Q

0.11

Relative Volume

0.97

Beta

0.45

Ticker: ASND

18 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2025-11-10	ASND	195.95	0.53	8.88	6850
2025-11-11	ASND	200.84	0.52	0.20	6819
2025-11-12	ASND	200.09	0.49	0.24	7239
2025-11-13	ASND	206.63	0.47	0.20	8184
2025-11-14	ASND	204.4	0.45	0.27	10073
2025-11-17	ASND	216.63	0.39	1.48	12455
2025-11-18	ASND	217.01	0.44	1.39	13044
2025-11-19	ASND	212.43	0.50	0.27	13886
2025-11-20	ASND	209.35	0.46	1.13	16862
2025-11-21	ASND	210.49	0.47	0.51	17027
2025-11-24	ASND	209	0.44	0.84	15817
2025-11-25	ASND	206.39	0.45	0.71	16025
2025-11-26	ASND	210.1	0.46	2.07	16358
2025-12-01	ASND	211.07	0.47	1.16	16592
2025-12-02	ASND	202.67	0.50	0.45	17123
2025-12-03	ASND	200.52	0.48	0.02	16982
2025-12-04	ASND	208.53	0.46	0.11	17492
2025-12-05	ASND	205.48	0.46	0.14	17579
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

18 items 1 of 1

18 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-11-10	ASND	196.01	90.8	416.5	-2.21
2025-11-11	ASND	201.16	90.8	423.6	-2.21
2025-11-12	ASND	200.15	90.8	417.2	-2.21
2025-11-13	ASND	206.50	90.8	424.1	-2.21
2025-11-14	ASND	204.51	93.8	376.0	-3.28
2025-11-17	ASND	216.56	93.8	390.3	-3.28
2025-11-18	ASND	216.92	106.3	378.3	-3.19
2025-11-19	ASND	212.15	106.3	373.3	-3.19
2025-11-20	ASND	209.35	106.3	375.0	-3.19
2025-11-21	ASND	210.16	68.8	378.4	-3.41
2025-11-24	ASND	208.80	68.8	376.0	-3.41
2025-11-25	ASND	206.65	72.9	375.3	-3.38
2025-11-26	ASND	210.09	72.9	380.9	-3.38
2025-12-01	ASND	210.85	72.9	375.9	-3.38
2025-12-02	ASND	202.16	72.9	368.8	-3.38
2025-12-03	ASND	200.50	72.9	375.6	-3.38
2025-12-04	ASND	208.57	72.9	385.7	-3.38
2025-12-05	ASND	205.44	72.9	374.5	-3.38
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

18 items 1 of 1

18 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-11-10	ASND	0.00	-5.52	5.69
2025-11-11	ASND	0.00	-5.52	5.69
2025-11-12	ASND	0.00	-5.52	5.90
2025-11-13	ASND	0.00	-5.52	5.90
2025-11-14	ASND	0.00	-5.52	5.90
2025-11-17	ASND	0.00	-3.91	0
2025-11-18	ASND	0.00	-3.91	5.85
2025-11-19	ASND	0.00	-3.91	5.85
2025-11-20	ASND	0.00	-3.91	5.87
2025-11-21	ASND	0.00	-3.91	5.87
2025-11-24	ASND	0.00	1.61	5.87
2025-11-25	ASND	0.00	1.61	5.87
2025-11-26	ASND	0.00	1.61	4.94
2025-12-01	ASND	0.00	1.82	4.94
2025-12-02	ASND	0.00	1.82	4.94
2025-12-03	ASND	0.00	1.82	4.94
2025-12-04	ASND	0.00	1.82	4.94
2025-12-05	ASND	0.00	1.82	4.94
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

18 items 1 of 1

Last Quarter Act. EPS

-1.17

Avg. EPS Est. Current Quarter

-0.17

Avg. EPS Est. Next Quarter

0.39

Insider Transactions

Institutional Transactions

1.82

Beta

0.45

Average Sales Estimate Current Quarter

246

Average Sales Estimate Next Quarter

282

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

-61.7

Target Price

254.83

P/E

Forward P/E

47.42

PEG

P/S

17.42

P/B

P/Free Cash Flow

EPS

-4.25

Average EPS Est. Cur. Y

-3.38

EPS Next Y. (Est.)

3.18

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-35.52

Relative Volume

0.97

Return on Equity vs Sector %

106.9

Return on Equity vs Industry %

121.8

EPS 1 7Days Diff

EPS 1 30Days Diff

-1.17

EBIT Estimation

374.5

Ascendis Pharma A/S

Sector: Healthcare

Industry: Biotechnology

Employees: 1017

Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Denmark, rest of Europe, North America, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is based in Hellerup, Denmark.

stock quote shares ASND – Ascendis Pharma A/S Stock Price stock today

news today ASND – Ascendis Pharma A/S stock forecast ,stock prediction 2023 2024 2025

marketwatch ASND – Ascendis Pharma A/S yahoo finance google finance

stock history ASND – Ascendis Pharma A/S invest stock market

stock prices ASND premarket after hours

ticker ASND fair value insiders trading

GMAB – Genmab A/S

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: GMAB

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

NVO – Novo Nordisk A/S

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: NVO

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

Last Quarter Act. EPS

Average EPS Est. Cur. Y

Last Quarter Act. EPS

Average EPS Est. Cur. Y

Last Quarter Act. EPS

Average EPS Est. Cur. Y